Phaseline

Companies › Maia Biotechnology

Maia Biotechnology: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 2; Oncology; next expected readout Jul 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
6-Thio-2'-Deoxyguanosine
Telomere targeting agent; preferentially incorporated into telomeres in telomerase-positiv
–Phase 3Carcinoma, Non-Small -Cell Lung; Carcinoma, Non-Small-Cell LungJul 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT069083046-Thio-2'-DeoxyguanosinePhase 3Carcinoma, Non-Small -Cell LungOncologyJul 2027
NCT052089446-Thio-2'-DeoxyguanosinePhase 2Carcinoma, Non-Small-Cell LungOncologySep 2027

From the company's SEC filings

Cash of $0m on 2026-09-30

Press releases filed as 8-K in the last year:

Private offerings reported to the SEC (Form D)

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals FutureGen Biopharmaceutical (Beijing) Epizyme CanariaBio pharmaand

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.